株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の抗肥満薬市場:2017〜2027年

Global Anti-Obesity Drugs Market Forecast 2017-2027: Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics and Others

発行 Visiongain Ltd 商品コード 178609
出版日 ページ情報 英文 205 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=154.30円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界の抗肥満薬市場:2017〜2027年 Global Anti-Obesity Drugs Market Forecast 2017-2027: Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics and Others
出版日: 2017年01月12日 ページ情報: 英文 205 Pages
概要

当レポートでは、世界における肥満症の治療薬市場の収益予測と成長率、市場シェア、研究開発動向などをまとめ、その結果をお届けいたします。

第1章 レポート概要

第2章 抗肥満薬市場のイントロダクション

  • 肥満とは
  • 肥満原因およびリスク因子
  • 肥満測定
  • 肥満の疫学
  • 肥満の人道的および経済的負担
  • 予防と治療

第3章 世界の抗肥満薬市場のイントロダクション

  • 市場構造
  • 市場定義および調査範囲
  • 作用機序別分類
  • 革新的治療薬およびジェネリック薬別分類
  • 処方薬およびOTC薬別分類
  • 治療期間別分類

第4章 世界の抗肥満薬市場

  • 世界の抗肥満薬市場の実績
  • 世界の抗肥満薬市場の予測
  • 作用機序別市場
  • 革新的治療薬およびジェネリック薬別市場
  • 処方薬およびOTC薬別市場
  • 治療期間別市場

第5章 主要な抗肥満薬

  • 売上高の実績および予測
  • 革新的な治療薬
  • ジェネリック薬

第6章 主要国市場の予測

  • 地理的内訳
  • 地域別予測
  • 米国市場
  • EU5ヵ国地域市場
  • BRIC地域市場
  • 日本市場

第7章 肥満治療の研究開発

  • パイプライン治療薬の最新作用機序
  • 有効なパイプライン治療薬
  • 将来有望なパイプライン治療薬

第8章 価格決定および償還概要

  • 米国
  • EU
  • 医療費支払い者の視点

第9章 世界の抗肥満薬の主要メーカーと最新動向

  • Novo Nordisk
  • Orexigen/Takeda
  • Arena/Eisai
  • F. Hoffmann-La Roche Ltd.
  • Vivus
  • Teva
  • GSK Consumer Healthcare

第10章 エグゼクティブサマリーおよび提言

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0161

The global anti-obesity drugs market is expected to grow at a CAGR of 27.1% in the first half of the forecast period and CAGR of 38.7% in the second half of the forecast period. The market is expected to grow at a CAGR of 32.8% from 2016 to 2027. The market is estimated at $1,058 million in 2016, $3,513 million in 2021, and $24,063 million in 2027.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 205-page report you will receive 78 tables and 140 figures - all unavailable elsewhere.

The 205-page report provides clear detailed insight into the global anti-obesity drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Anti-Obesity Drugs market forecasts from 2017-2027
  • Anti-Obesity Drugs National market forecasts from 2017-2027, covering:
    • United States
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Japan
    • China
    • India
    • Brazil
    • Russia
    • RoW
  • Anti-Obesity Drugs submarket forecasts from 2017-2027, by Mechanisms of Action:
    • Incretin mimetics/GLP-1 agonists
    • SNDRIs
    • Lipase inhibitors
    • Serotonin receptor agonists
    • Sympathomimetic-GABA receptor agonists
    • Sympathomimetics
    • Others
  • Anti-Obesity Drugs submarket forecasts from 2017-2027, by Duration of Therapy:
    • Short-term Drugs
    • Long-term Drugs
  • Anti-Obesity Drugs submarket forecasts from 2017-2027, segmented by Innovator vs Generic Drugs
  • Anti-Obesity Drugs submarket forecasts from 2017-2027, segmented by Prescription vs OTC Drugs
  • Analysis of the key factors driving and restraining the growth of the anti-obesity drugs market from 2017-2027
  • Pricing and Reimbursement overview of the anti-obesity drugs market
  • Assessment of selected leading companies that hold major market shares in the anti-obesity drugs market.

Visiongain's study is intended for anyone requiring commercial analyses for the Anti-Obesity Drugs Market and leading companies. You find data, trends and predictions.

Buy our report today Global Anti-Obesity Drugs Market Forecast 2017-2027: Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics and Others.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Why You Should Read This Report
  • 1.2. How This Report Delivers
  • 1.3. Key Questions Answered by This Analytical Report
  • 1.4. Who is This Report for?
  • 1.5. Methodology
    • 1.5.1. Primary Research
    • 1.5.2. Secondary Research
    • 1.5.3. Market Evaluation & Forecasting Methodology
  • 1.6. Frequently Asked Questions
  • 1.7. Associated Reports
  • 1.8. About Visiongain

2. Introduction to Obesity

  • 2.1. What is Obesity?
    • 2.1.1. Types of obesity
      • 2.1.1.1. Central Obesity / Android Type
      • 2.1.1.2. Peripheral Obesity/ Gynoid Type
  • 2.2. What are the causes and risk factors of obesity?
    • 2.2.1. Energy Imbalance
    • 2.2.2. Genetic Predisposition
    • 2.2.3. Unhealthy Diet
    • 2.2.4. Health Conditions and Medicines
    • 2.2.5. Emotional Factors
    • 2.2.6. Age
    • 2.2.7. Pregnancy
    • 2.2.8. Lack of Sleep
    • 2.2.9. Smoking
  • 2.3. Obesity Measurement
    • 2.3.1. BMI
    • 2.3.2. Waist circumference
    • 2.3.3. Index of Central Obesity
    • 2.3.4. Bioelectrical Impedance Analysis
    • 2.3.5. New Approaches/Techniques
  • 2.4. Epidemiology of Obesity
    • 2.4.1. Epidemiology by Geography
    • 2.4.2. Epidemiology by Country
    • 2.4.3. Historical Prevalence in Major Markets
    • 2.4.1. Forecast of Obesity Prevalence in Major Markets
  • 2.5. Humanistic and Economic Burden
    • 2.5.1. Mortality
    • 2.5.2. Morbidity
      • 2.5.2.1. Disability-adjusted life year (DALY)
      • 2.5.2.2. Years Lost due to Disability (YLD)
      • 2.5.2.3. Years of Life Lost(YLL)
        • 2.5.2.3.1. Type-2 diabetes
        • 2.5.2.3.2. Dyslipidaemia
        • 2.5.2.3.3. Hypertension
        • 2.5.2.3.4. Stroke & Heart failure
        • 2.5.2.3.5. Non-alcoholic fatty liver disease (NAFLD)
        • 2.5.2.3.6. Osteoarthritis
        • 2.5.2.3.7. Psychological disorders
    • 2.5.3. Economic Impact
  • 2.6. Obesity: Prevention and Treatment
    • 2.6.1. Lifestyle changes
    • 2.6.2. Pharmacotherapy
    • 2.6.3. Other treatments

3. Introduction to the Global Anti-Obesity Drugs Market

  • 3.1. Market Structure
  • 3.2. Market Definition and Scope
  • 3.3. Classification by Mechanism of Action
    • 3.3.1. Incretin Mimetics/GLP-1 Agonists
    • 3.3.2. Lipase Inhibitors
    • 3.3.3. Serotonin-norepinephrine-dopamine Reuptake (SNDRI) Inhibitors
    • 3.3.4. Serotonin Receptor Agonists
    • 3.3.5. Sympathomimetics
    • 3.3.6. Sympathomimetic-GABA Receptor Agonists
    • 3.3.7. Others
  • 3.4. Classification by Innovator or Generics Drugs
    • 3.4.1. Innovator Drugs
    • 3.4.2. Generics Drugs
  • 3.5. Classification by Prescription or OTC drugs
    • 3.5.1. Prescription drugs
    • 3.5.2. OTC drugs
  • 3.6. Classification by Duration of Therapy
    • 3.6.1. Short-term drugs
    • 3.6.2. Long-term drugs

4. Global Anti-Obesity Drugs Market 2017-2027

  • 4.1. Global Anti-Obesity Drugs Market 2016
  • 4.2. Global Anti-Obesity Drugs Market Forecast 2017-2027
  • 4.3. Market Segmentation by Mechanism of Action
    • 4.3.1. Forecast 2017-2027
      • 4.3.1.1. Incretin mimetics/GLP-1 Agonists
      • 4.3.1.2. Lipase Inhibitors
      • 4.3.1.3. Serotonin-norepinephrine-dopamine Reuptake Inhibitors (SNDRI)
    • 4.3.2. Serotonin Receptor Agonists
      • 4.3.2.1. Sympathomimetic-GABA Receptor Agonists
      • 4.3.2.2. Sympathomimetics
      • 4.3.2.3. Others
    • 4.3.3. Market Share Forecast 2017-2027
  • 4.4. Market Segmentation by Innovator and Generics Drugs
    • 4.4.1. Forecast 2017-2027
      • 4.4.1.1. Innovator Drugs
      • 4.4.1.2. Generics
    • 4.4.2. Market Share Forecast 2017-2027
  • 4.5. Market Segmentation by Prescription and OTC Drugs
    • 4.5.1. Forecast 2017-2027
      • 4.5.1.1. Prescription Drugs
      • 4.5.1.2. OTC Drugs
    • 4.5.2. Market Share Forecast 2017-2027
  • 4.6. Market Segmentation by Duration of Therapy
    • 4.6.1. Forecast 2017-2027
      • 4.6.1.1. Short-term Anti-Obesity Drugs
      • 4.6.1.2. Long-term Anti-Obesity Drugs
    • 4.6.2. Market Share Forecast 2017-2027
  • 4.7. Overall Global Anti-Obesity Drugs Market Drivers, Restraints and Trends

5. Leading Anti-Obesity Drugs

  • 5.1. Snapshot of Anti-Obesity Drugs' 2016 Sales, Historical Sales, & Forecast 2017-2027
  • 5.2. Innovator Drugs
    • 5.2.1. Saxenda
      • 5.2.1.1. Drug Profile
      • 5.2.1.2. Historical Sales
      • 5.2.1.3. Forecast 2017-2027
      • 5.2.1.4. Sales by Geography, 2016
    • 5.2.2. Contrave / Mysimba
      • 5.2.2.1. Drug Profile
      • 5.2.2.2. Historical Sales
      • 5.2.2.3. Forecast 2017-2027
      • 5.2.2.4. Sales by Geography, 2016
    • 5.2.3. Belvig
      • 5.2.3.1. Drug Profile
      • 5.2.3.2. Historical Sales
      • 5.2.3.3. Forecast 2017-2027
      • 5.2.3.4. Sales by Geography, 2016
    • 5.2.4. Qysmia
      • 5.2.4.1. Historical Sales
      • 5.2.4.2. Forecast 2017-2027
    • 5.2.5. Xenical and Alli
      • 5.2.5.1. Historical Sales
      • 5.2.5.2. Sales by Geography, 2016
      • 5.2.5.3. Forecast 2017-2027
    • 5.2.6. Cametor/Oblean
    • 5.2.7. Lomaira
  • 5.3. Generics
    • 5.3.1. Orlistat
      • 5.3.1.1. Historical Sales
    • 5.3.2. Sibutramine
      • 5.3.2.1. Historical Sales
    • 5.3.3. Adipex
      • 5.3.3.1. Historical Sales
    • 5.3.4. Phentermine
      • 5.3.4.1. Historical Sales

6. Leading National Markets Forecast 2017-2027

  • 6.1. Geographical Breakdown of Global Anti-Obesity Drugs Market, 2016
    • 6.1.1. Region-wise Breakdown of Global Anti-Obesity Drugs Market, 2016
    • 6.1.2. Country-wise Breakdown of Global Anti-Obesity Drugs Market, 2016
  • 6.2. Region-wise Forecast of Global Anti-Obesity Drugs Market, 2017-2027
  • 6.3. Anti-obesity Drugs Market in the US, 2016
    • 6.3.1. Market Forecast of the US, 2017-2027
  • 6.4. Anti-obesity Drugs Market in the EU5 Region, 2016
    • 6.4.1. Market Forecast of the EU5 Countries, 2017-2027
      • 6.4.1.1. The UK
      • 6.4.1.2. Spain
      • 6.4.1.3. Italy
      • 6.4.1.4. Germany
      • 6.4.1.5. France
  • 6.5. Anti-Obesity Drugs Market in the BRIC Region, 2016
    • 6.5.1. Market Forecast of the BRIC Countries
      • 6.5.1.1. Brazil
      • 6.5.1.2. Russia
      • 6.5.1.3. India
      • 6.5.1.4. China
  • 6.6. Anti-Obesity Drugs Market in Japan Region, 2016

7. Research and Development for Treating Obesity

  • 7.1. Novel Mechanism of Action of Pipeline Drugs
  • 7.2. Active Pipeline Molecules
  • 7.3. Promising Potential Pipeline Molecules
    • 7.3.1. Phase III Molecules
      • 7.3.1.1. BTI-320
    • 7.3.2. Phase II Molecules
      • 7.3.2.1. Oxyntolong
      • 7.3.2.2. Antisense FGFR4 oligo, Verva
      • 7.3.2.3. S-237648
      • 7.3.2.4. Setmelanotide
      • 7.3.2.5. Bupropion + zonisamide SR
      • 7.3.2.6. Semaglutide
      • 7.3.2.7. LIK066
      • 7.3.2.8. Tesofensine
      • 7.3.2.9. LIPO-202
      • 7.3.2.10. Canagliflozin and Phentermine
      • 7.3.2.11. OBEP-100
      • 7.3.2.11.1. Efpeglenatide
      • 7.3.2.12. EMP16
      • 7.3.2.13. MEDI-0382

8. Pricing and Reimbursement Overview

  • 8.1. US
  • 8.2. EU
  • 8.3. Payers Perspective

9. Leading Companies in Global Anti-Obesity Drugs Market, 2016

  • 9.1. Novo Nordisk
  • Source: visiongain 2017
    • 9.1.1. Obesity Care - To Establish its presence
  • 9.2. Orexigen/Takeda
    • 9.2.1. Collaboration Agreement with Takeda Pharmaceutical Company Limited
    • 9.2.2. Collaboration Agreement with Valeant
  • 9.3. Arena/Eisai
    • 9.3.1. Collaboration Agreement with Eisai Co., Ltd.
    • 9.3.2. Collaboration Agreement with Other Companies
  • 9.4. F. Hoffmann-La Roche Ltd.
  • 9.5. Vivus
  • 9.6. Teva
  • 9.7. GSK Consumer Healthcare

10. Executive Summary and Recommendations

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 2.1: WHO BMI Cut Off Points
  • Table 2.2: Classification of Overweight and Obesity by BMI, Waist Circumference, and Associated Disease Risk
  • Table 2.3: Forecast of Obesity Prevalence in Major Markets (US, EU5, BRIC, and Japan), Both Sexes, aged >18 years, 2016-2027, million, CAGR (2016-2027) %
  • Table 3.1: Mechanism of Action of Innovator Drugs for the treatment of Obesity
  • Table 3.2: List of Innovator Drugs for the treatment of Obesity
  • Table 3.3: List of Prescription Drugs for the treatment of Obesity
  • Table 3.4: Long-term Prescription Drugs for the treatment of Obesity
  • Table 4.1: Global Anti-Obesity Drugs Market by Submarkets: Revenue ($m), and Market Share (%), 2016
  • Table 4.2: Global Anti-Obesity Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.3: Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.4: Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action 2016-2027: AGR (%)
  • Table 4.5: Global Anti-Obesity Incretin mimetics/GLP-1 Agonist Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.6: List of Active GLP-1 agonists in Clinical Pipeline
  • Table 4.7: Global Anti-Obesity Lipase Inhibitor Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.8: List of Active SNDRI agonists in Clinical Pipeline
  • Table 4.9: Global Anti-Obesity Serotonin-norepinephrine-Dopamine Reuptake Inhibitor Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.10: Global Anti-Obesity Serotonin Receptor Agonist Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.11: Global Anti-Obesity Sympathomimetic-GABA Receptor Agonist Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.12: Global Anti-Obesity Sympathomimetic Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.13: Global Anti-Obesity Other Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.14: Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action 2016-2027: Market Share (%) Source: visiongain 2017
  • Table 4.15: Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.16: Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics 2016-2027: AGR (%)
  • Table 4.17: Global Anti-Obesity Innovator Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.18: Global Anti-Obesity Generic Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.19: Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics 2016-2027: Market Share (%) Source: visiongain 2017
  • Table 4.20: Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.21: Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs 2016-2027: AGR (%)
  • Table 4.22: Global Anti-Obesity Prescription Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.23: Global Anti-obesity OTC Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.24: Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs 2016-2027: Market Share (%) Source: visiongain 2017
  • Table 4.25: Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.26: Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy 2016-2027: AGR (%)
  • Table 4.27: Global Anti-Obesity Short-term Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.28: Global Anti-Obesity Long-term Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.29: Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy 2016-2027: Market Share (%) Source: visiongain 2017
  • Table 5.1: Leading Anti-Obesity Drug Sales, Revenue($m), Market Share (%), 2016
  • Table 5.2: Saxenda Sales Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.3: Contrave Sales Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.4: Belvig Sales Forecast 2016-2027: Revenue ($million), AGR (%), CAGR (%)
  • Table 5.5: Qysmia Sales Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.6: Alli Sales Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.1: Global Anti-Obesity Drugs Market by Region: Revenue ($m), and Market Share (%), 2016
  • Table 6.2: Global Anti-Obesity Drugs Market by Country: Revenue ($m), and Market Share (%), 2016
  • Table 6.3: Global Anti-Obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%),2016-2027
  • Table 6.4: Global Anti-Obesity Drugs Market by Region: AGR 2016-2027 (%) Source: visiongain 2017
  • Table 6.5: Global Anti-Obesity Drugs Market by Region: Market Share Forecast 2017-2027 (%) Source: visiongain 2017
  • Table 6.6: Anti-Obesity Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.7: Anti-obesity Drugs Market Forecast in EU5 Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 6.8: Anti-obesity Drugs Market by EU Region: Market Share Forecast 2017-2027 (%) Source: visiongain 2017
  • Table 6.9: Anti-Obesity Drugs Market Forecast by EU5 Region: AGR 2016-2027 (%) Source: visiongain 2017
  • Table 6.10: Anti-Obesity Drugs Market Forecast in the UK: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 6.11: Anti-obesity Drugs Market Forecast in Spain: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 6.12: Anti-obesity Drugs Market Forecast in Italy: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 6.13: Anti-Obesity Drugs Market Forecast in Germany: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 6.14: Anti-Obesity Drugs Market Forecast in France: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 6.15: Anti-Obesity Drugs Market Forecast in BRIC Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 6.16: Anti-Obesity Drugs Market Forecast in Brazil Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 6.17: Anti-Obesity Drugs Market Forecast in Russia Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 6.18: Anti-Obesity Drugs Market Forecast in India Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 6.19: Anti-Obesity Drugs Market Forecast in China: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 6.20: Anti-Obesity Drugs Market Forecast in Japan: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 7.1: Active Pipeline Molecules under Development for Treating Obesity
  • Table 9.1: Innovator Drugs' Originator-Licensee Information
  • Table 9.2: Novo Nordisk A/S: Overview 2016
  • Table 9.3: Novo Nordisk: List of Active Clinical Pipeline Molecules
  • Table 9.4: Orexigen: Overview 2016
  • Table 9.5: Arena: Overview 2016
  • Table 9.6: Roche: Overview 2016
  • Table 9.7: Vivus: Overview 2016

List of Figures

  • Figure 2.1: Prevalence of Overweight and Obese Population by WHO Region, Ages 18+, 2014
  • Figure 2.2: Prevalence of Overweight, Ages 18+, 2010-2014, Age Standardized Estimate: Both Sexes 2014
  • Figure 2.3: Prevalence of Obesity, Ages 18+, 2010-2014, Age Standardized Estimate: Both Sexes 2014
  • Figure 2.4: Prevalence of Obesity in OECD 32 Countries - population aged 15 years and over, 2013 or nearest year
  • Figure 2.5: Prevalence of Obesity in G7 and BRIC Countries - population aged 15 years and over, 2012 or nearest year, men, women, both sexes
  • Figure 2.6: Age-Standardized Obesity Prevalence Rate in Major Markets - Population aged 15 years and over, 1973-2012
  • Figure 2.7: Deaths due to Obesity in G7 and BRIC Nation: Absolute Number (000's), 2015
  • Figure 2.8: DALY's due to Obesity in G7 and BRIC Nation: Absolute Number (million), 2015
  • Figure 2.9: YLD's due to Obesity in G7 and BRIC Nation: Absolute Number (million), 2015
  • Figure 2.10: YLL's due to Obesity in G7 and BRIC Nation: Absolute Number (000's), 2015
  • Figure 3.1: Global Anti-obesity Drugs Market Segmentation Overview
  • Figure 3.2: Anti-Obesity Drugs Classification by Mechanism of Action, 2016
  • Figure 4.1: Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action, Market Share 2016 (%)
  • Figure 4.2: Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics, Market Share 2016 (%)
  • Figure 4.3: Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs, Market Share 2016 (%)
  • Figure 4.4: Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy, Market Share 2016 (%)
  • Figure 4.5: Global Anti-Obesity Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.6: Global Anti-Obesity Drugs Market Size of Markets by Mechanism of Action 2016, Revenue ($m)
  • Figure 4.7: Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action, Market Share 2016 (%)
  • Figure 4.8: Global Anti-obesity Drugs Market Segmentation by Mechanism of Action 2016-2027: Revenue ($m), Global AGR (%)
  • Figure 4.9: Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action 2016 and 2027: Revenue ($m), CAGR 2016-2027(%)
  • Figure 4.10: Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action 2016-2027: AGR (%)
  • Figure 4.11: Global Anti-Obesity Incretin mimetics/GLP-1 Agonist Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.12: Global Anti-Obesity Lipase Inhibitor Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.13: Global Anti-Obesity Serotonin-norepinephrine-Dopamine Reuptake Inhibitor Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.14: Global Anti-Obesity Serotonin Receptor Agonist Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.15: Global Anti-Obesity Sympathomimetic-GABA Receptor Agonist Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.16: Global Anti-Obesity Sympathomimetic Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.17: Global Anti-Obesity Other Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.18: Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action 2016-2027: Market Share (%)
  • Figure 4.19: Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action: Market Share Forecast 2017 (%)
  • Figure 4.20: Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action: Market Share 2027 (%)
  • Figure 4.21: Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics, Revenue 2016 ($m)
  • Figure 4.22: Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics, Market Share 2016 (%)
  • Figure 4.23: Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics 2016-2027: Revenue ($m), Global AGR (%)
  • Figure 4.24: Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics: Revenue 2016 and 2027 ($m), CAGR 2016-2027 (%)
  • Figure 4.25: Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics 2016-2027: AGR (%)
  • Figure 4.26: Global Anti-Obesity Innovator Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.27: Global Anti-Obesity Generic Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.28: Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics 2016-2027: Market Share (%)
  • Figure 4.29: Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics, Market Share Forecast 2017 (%)
  • Figure 4.30: Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics: Market Share Forecast 2027 (%)
  • Figure 4.31: Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs, Revenue 2016 ($m)
  • Figure 4.32: Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs, Market Share 2016 (%)
  • Figure 4.33: Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs 2016-2027: Revenue ($m), Global AGR (%)
  • Figure 4.34: Global Anti-obesity Drugs Market Segmentation by Prescription and OTC Drugs: Revenue 2016 and 2027 ($m), CAGR 2016-2027 (%)
  • Figure 4.35: Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs 2016-2027: AGR (%)
  • Figure 4.36: Global Anti-Obesity Prescription Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.37: Global Anti-obesity OTC Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.38: Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs 2016-2027: Market Share (%)
  • Figure 4.39: Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs, Market Share Forecast 2017 (%)
  • Figure 4.40: Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs: Market Share Forecast 2027 (%)
  • Figure 4.41: Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy, Revenue 2016 ($m)
  • Figure 4.42: Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy, Market Share 2016 (%)
  • Figure 4.43: Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy 2016-2027: Revenue ($m)
  • Figure 4.44: Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy: Revenue 2016 and 2027 ($m), CAGR 2016-2027 (%)
  • Figure 4.45: Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy 2016-2027: AGR (%)
  • Figure 4.46: Global Anti-Obesity Short-term Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.47: Global Anti-Obesity Long-term Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 4.48: Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy 2016-2027: Market Share (%)
  • Figure 4.49: Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy, Market Share Forecast 2017 (%)
  • Figure 4.50: Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy: Market Share Forecast 2027 (%)
  • Figure 4.51: Trends in Global Anti-Obesity Drugs Market
  • Figure 4.52: SWOT Analysis of the Global Anti-Obesity Drugs Market
  • Figure 5.1: Leading Anti-Obesity Drug Sales, Revenue ($m), 2016
  • Figure 5.2: Leading Anti-Obesity Drug Sales, Market Share (%), 2016
  • Figure 5.3: Anti-Obesity Drugs Sales Forecast, Market Share (%), 2027
  • Figure 5.4: Leading Anti-Obesity Drugs, Historical Sales, Revenue ($m), 2011-2016
  • Figure 5.5: Anti-Obesity Drugs, Historical Sales Trend, Revenue ($m), 2011-2016
  • Figure 5.6: Global Anti-Obesity Innovator Drugs Market, Market Share by Individual Drug (%), 2016
  • Figure 5.7: Global Anti-Obesity Innovator Drugs Market Forecast, Market Share by Individual Drug (%), 2027
  • Figure 5.8: Saxenda Global Sales: Revenue ($million), 2015-2016
  • Figure 5.9: Saxenda Sales Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 5.10: Saxenda Sales by Geography: Market Share (%), 2016
  • Figure 5.11: Contrave Global Sales: Revenue ($million), 2014-2016
  • Figure 5.12: Contrave Sales Forecast 2016-2027: Revenue ($million), AGR (%)
  • Figure 5.13: Contrave Sales by Geography: Market Share (%), 2016
  • Figure 5.14: Belviq Global Sales: Revenue ($million), 2013-2016
  • Figure 5.15: Belvig Sales Forecast 2016-2027: Revenue ($million), AGR (%)
  • Figure 5.16: Belviq Sales by Geography: Market Share (%), 2016
  • Figure 5.17: Qysmia Global Sales: Revenue ($million), 2013-2016
  • Figure 5.18: Qysmia Sales Forecast 2016-2027: Revenue ($million), AGR (%)
  • Figure 5.19: Qysmia Sales by Geography: Market Share (%), 2016
  • Figure 5.20: Xenical Global Sales: Revenue ($million), 2011-2016
  • Figure 5.21: Alli Global Sales: Revenue ($million), 2011-2016
  • Figure 5.22: Xenical Sales by Geography: Market Share (%), 2016
  • Figure 5.23: Alli Sales by Geography: Market Share (%), 2016
  • Figure 5.24: Alli Sales Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 5.25: Global Anti-obesity Generics Market, Market Share by Individual Compound (%), 2016
  • Figure 5.26: Orlistat Global Sales: Revenue ($m), 2011-2016
  • Figure 5.27: Sibutramine Global Sales: Revenue ($million), 2011-2016
  • Figure 5.28: Adipex Global Sales: Revenue ($million), 2011-2016
  • Figure 5.29: Phentermine Global Sales: Revenue ($m), 2011-2016
  • Figure 6.1: Global Anti-Obesity Drugs Market Segmentation by Region/Country
  • Figure 6.2: Global Anti-Obesity Drugs Market by Region: Revenue ($m)
  • Figure 6.3: Global Anti-Obesity Drugs Market by Region: Market Share 2016 (%)
  • Figure 6.4: Global Anti-Obesity Drugs Market by Country: Revenue ($m), 2016
  • Figure 6.5: Global Anti-Obesity Drugs Market by Country: Market Share (%), 2016
  • Figure 6.6: Global Anti-Obesity Drugs Market Forecast by Region: Revenue ($m), Global AGR (%), 2016-2027
  • Figure 6.7: Global Anti-Obesity Drugs Market Forecast by Region 2016, 2022, 2027: Revenue ($m), CAGR 2016-2027 (%)
  • Figure 6.8: Global Anti-Obesity Drugs Market by Region: AGR 2016-2027 (%)
  • Figure 6.9: Global Anti-Obesity Drugs Market by Region: Market Share Forecast 2017-2027 (%)
  • Figure 6.10: Global Anti-Obesity Drugs Market by Region: Market Share Forecast 2017 (%)
  • Figure 6.11: Global Anti-Obesity Drugs Market by Region: Market Share Forecast 2022 (%)
  • Figure 6.12: Global Anti-Obesity Drugs Market by Region: Market Share Forecast 2027 (%)
  • Figure 6.13: Anti-obesity Drugs Market in the US: 2016 Revenue ($m), Market Share %
  • Figure 6.14: Anti-obesity Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%)
  • Figure 6.15: Anti-obesity Drugs Market in the EU5 2016: Global Market Share (%)
  • Figure 6.16: Anti-Obesity Drugs Market in the EU5 Countries 2016: Market Share (%)
  • Figure 6.17: Anti-Obesity Drugs Market Forecast in the EU5 Countries 2016-2027: Revenue ($m), EU5 AGR (%)
  • Figure 6.18: Anti-Obesity Drugs Market Forecast in the EU5 Countries 2016 and 2027: Revenue ($m), CAGR 2016-2027 (%)
  • Figure 6.19: Anti-Obesity Drugs Market by EU5 Region: Market Share Forecast 2017-2027 (%)
  • Figure 6.20: Anti-Obesity Drugs Market Forecast by EU5 Region: Global Market Share 2027(%)
  • Figure 6.21: Anti-Obesity Drugs Market Forecast by EU5 Region: Market Share 2017(%)
  • Figure 6.22: Anti-Obesity Drugs Market Forecast by EU5 Region: Market Share 2027 (%)
  • Figure 6.23: Global Anti-Obesity Drugs Market Forecast by EU5 Region: AGR 2016-2027 (%)
  • Figure 6.24: Anti-Obesity Drugs Market Forecast in the UK: Revenue ($m), AGR (%),2016-2027
  • Figure 6.25: Anti-obesity Drugs Market Forecast in Spain: Revenue ($m), AGR (%), 2016-2027
  • Figure 6.26: Anti-Obesity Drugs Market Forecast in Italy: Revenue ($m), AGR (%), 2016-2027
  • Figure 6.27: Anti-Obesity Drugs Market Forecast in Germany: Revenue ($m), AGR (%), 2016-2027
  • Figure 6.28: Anti-Obesity Drugs Market Forecast in France: Revenue ($m), AGR (%), 2016-2027
  • Figure 6.29: Anti-Obesity Drugs Market in the BRIC Region: Global Market Share 2016 (%)
  • Figure 6.30: Anti-Obesity Drugs Market in the BRIC Countries 2016: Market Share (%)
  • Figure 6.31: Anti-Obesity Drugs Market Forecast in the BRIC Countries 2016-2027: Revenue ($m), BRIC AGR (%)
  • Figure 6.32: Anti-Obesity Drugs Market Forecast in the BRIC Countries 2016 and 2027: Revenue ($m), CAGR 2016-2027 (%)
  • Figure 6.33: Anti-Obesity Drugs Market Forecast by BRIC Region: Global Market Share 2027(%)
  • Figure 6.34: Anti-Obesity Drugs Market Forecast by BRIC Region: Market Share 2017(%)
  • Figure 6.35: Anti-Obesity Drugs Market Forecast by BRIC Region: Market Share 2027 (%)
  • Figure 6.36: Anti-Obesity Drugs Market Forecast in the Brazil: Revenue ($m), AGR (%), 2016-2027
  • Figure 6.37: Anti-Obesity Drugs Market Forecast in the Russia: Revenue ($m), AGR (%),2016-2027
  • Figure 6.38: Anti-Obesity Drugs Market Forecast in the India: Revenue ($m), AGR (%),2016-2027
  • Figure 6.39: Anti-Obesity Drugs Market Forecast in China: Revenue ($m), AGR (%),2016-2027
  • Figure 6.40: Anti-Obesity Drugs Market Forecast in Japan: Revenue ($m), AGR (%),2016-2027
  • Figure 7.1: Anti-obesity Clinical Pipeline Segmentation by Phase, 2016
  • Figure 7.2: Anti-obesity Pipeline Segmentation by Mechanism of Action, 2016
  • Figure 9.1: Global Anti-Obesity Drugs Market by Company: Revenue ($m)
  • Figure 9.2: Global Anti-Obesity Drugs Market by Company 2016: Market Share (%)
  • Figure 9.3: Novo Nordisk's 20-year R&D journey in Obesity - Milestones of Saxenda
  • Figure 10.1: Forecast of Obesity Prevalence in US, EU5, BRIC and Japan, ages 18+, Both sexes, 2016-2027
  • Figure 10.2: Global Anti-Obesity Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)

Companies Listed

  • ADial Pharmaceuticals
  • Akrimax Pharmaceuticals
  • Arena Pharmaceuticals
  • AstraZeneca
  • Biophytis
  • Boehringer Ingelheim
  • Boston Therapeutics
  • Diasome
  • Eisai
  • EMEA
  • Empros Pharma
  • FDA
  • GenePreDiT
  • GlaxoSmithKline (GSK)
  • Hanmi
  • Ildong Pharmaceuticals
  • Intarcia Therapeutics
  • Ionis Pharmaceuticals
  • Janssen Pharmaceuticals
  • KT&G Life Sciences
  • Kwang Dong
  • Medivation
  • Medlab Clinical
  • Neothetics
  • NGM Biopharmaceuticals
  • Novartis
  • Novo Nordisk
  • OPKO Health
  • Orexigen
  • Rhythm Pharmaceuticals
  • Roche
  • Saniona
  • Shionogi & Co., Ltd
  • Takeda
  • Teva
  • Valeant Pharmaceuticals
  • Virtici
  • Vivus
  • Xenetic Biosciences
  • Zafgen
Back to Top